Mironova Roumyana, Sredovska Angelina, Ivanov Ivan, Niwa Toshimitsu
Department of Gene Regulations, Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Ann N Y Acad Sci. 2008 Apr;1126:181-4. doi: 10.1196/annals.1433.006. Epub 2007 Dec 13.
We have recently shown that recombinant human interferon-gamma is affected by early stages of the Maillard reaction during its production in Escherichia coli. Over time, advanced glycation end products accumulated in the purified protein, accompanied with degradation, cross-linking, and a drop in the protein's biologic activity. Here, we provide further evidence for the presence of Maillard reaction products in another E. coli-derived therapeutic protein, interferon alfacon-1. These products might interfere with both treatment efficacy and patient safety.
我们最近发现，重组人干扰素-γ在大肠杆菌中生产时会受到美拉德反应早期阶段的影响。随着时间的推移，晚期糖基化终产物在纯化的蛋白质中积累，同时伴随着降解、交联以及蛋白质生物活性的下降。在此，我们提供了进一步的证据，证明在另一种大肠杆菌衍生的治疗性蛋白质——干扰素 alfacon-1 中存在美拉德反应产物。这些产物可能会干扰治疗效果和患者安全。
